Russia grants patent for another coronavirus vaccine

The St. Petersburg company Biocad (Biocad) received a patent for a vaccine against covid-19 . This is a recombinant vector vaccine based on adenovirus type 5, which can be used to induce specific immunity and prevent CORONAVIRUS infection. This was reported by TASS with reference to Rospatent.

One patent provides comprehensive protection for a vaccine both as a means of prevention and as a means of inducing immunity. “An integrated approach ensures the competitiveness of domestic development both in the Russian and foreign markets, provided that it is also patented abroad,” said Grigory Ivliev, HEAD of the service.

The patent description cited by the agency says that the vaccine is vector-based and based on type 5 adenovirus. After the drug is introduced into the human body, it develops specific immunity to SARS-CoV-2 through the use of a codon-optimized nucleic acid.

Biocad received approval from the Ministry of HEALTH to test its vaccine in July 2021. Two St. Petersburg medical organizations were chosen as bases for research: the Yuninova Research Center and the X7 Clinical Research Center.

360 people will take part in the tests. The first and second phases of the research should be completed by the end of 2026.